TRIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trinity Biotech PLC (TRIB) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has announced positive news regarding its EpiCapture product, the technical indicators suggest a bearish trend, and the financial performance remains weak with no YoY growth in revenue or net income. Additionally, there are no strong trading signals or significant trading sentiment to support immediate action.
The technical indicators for TRIB are bearish. The MACD histogram is negative and contracting, RSI is neutral at 33.067, and the moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.606, with resistance at 0.698. The pre-market price is down 1.96%, indicating further weakness.
The company announced positive results for its EpiCapture prostate cancer test, which has 85% clinical accuracy. It plans to commercialize the product in the U.S. market, addressing a significant demand in the $20 billion prostate cancer care market. The non-invasive nature of the test could attract more patients.
The company has weak financial performance with no YoY growth in revenue, net income, or EPS. The stock is also in a bearish technical trend, and there are no significant trading signals or sentiment from hedge funds, insiders, or congress trading data.
In Q3 2024, the company reported revenue of $15.15 million, net income of -$4.76 million, and EPS of -0.04, all showing no YoY growth. Gross margin stands at 35.44%.
No recent analyst ratings or price target changes are available for TRIB.
